scispace - formally typeset
J

Jennifer J. Arnold

Publications -  4
Citations -  927

Jennifer J. Arnold is an academic researcher. The author has contributed to research in topics: Verteporfin & Choroidal neovascularization. The author has an hindex of 4, co-authored 4 publications receiving 901 citations.

Papers
More filters
Journal ArticleDOI

Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin - 1-year results of a randomized clinical trial - VIP report no. 1

Jennifer J. Arnold, +292 more
- 01 Jan 2001 - 
TL;DR: Because photodynamic therapy with verteporfin can safely increase the chance of stabilizing or improving vision in patients with subfoveal CNV from pathologic myopia compared with a placebo, it is recommended ophthalmologists consider vertEPorfin therapy for treatment of such patients.
Journal ArticleDOI

Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3.

TL;DR: Initial reports that verteporfin therapy should be used to treat patients with AMD who have predominantly classic CNV, with or without occult CNV are supported, but it is suggested that further investigations should be performed to determine if lesions with a minimally classic composition might benefit when they are smaller and have lower levels of visual acuity.
Journal ArticleDOI

Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report no. 3.

TL;DR: Acute severe visual acuity decrease after PDT with verteporfin was an uncommon event; the risk did not outweigh the benefits of therapy previously reported and patients should be warned of the possibility of this serious adverse event.
Journal ArticleDOI

Immunosuppressive treatment of choroidal neovascularization associated with endogenous posterior uveitis

TL;DR: A role for immunosuppressive therapy in the treatment of CNV associated with endogenous posterior uveitis is supported, and a median follow-up of 15 months shows 9 of 17 eyes had an improvement in visual acuity.